AlloCyte Pharmaceuticals AG is the privately held Swiss company translating its proprietary
next-generation small molecule integrin pharmacology into therapies of transformative
potential for immune-mediated diseases of high medical need.
AlloCyte's team has established the categorical differentiation of diverse modes of integrin inhibition based
on their downstream effect profiles (Mancuso et al 2016).